ClinicalTrials.gg
CompletedNCT03271541Updated Oct 5, 2018

A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia

A Phase 2 interventional study of Bitopertin in Beta-Thalassemia, sponsored by Hoffmann-La Roche. Completed at 4 sites in 3 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-10-05.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies in beta-Thalassemia with a site in Italy — 8 open to participants now, 17 under way, 6 of them phase 3. beta-Thalassemia · Italy.

Enrollment
35th of 39
12 · median 55
Started
2017
with 4 others
Phase 2
18 of 49
2 open now
Registered
24th of 49
by date

Among the 49 studies in beta-Thalassemia with a site in Italy, this one is the 35th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2017, is one of 18 in phase 2, and was the 24th registered.

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

8 of the 49 studies in beta-Thalassemia with a site in Italy are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in beta-Thalassemia with a site in Italy, or all of them as a file.
02

Study summary

This proof-of-mechanism study is being performed to investigate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of multiple oral doses of bitopertin in adults with NTD beta-thalassemia.

This study consists of two parts:

Part 1 - The main study - 16 weeks in total: Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose.

Part 2 - Open Label Extension (OLE) - up to an additional 12 months. Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed. Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period.

03

Conditions studied

  • Beta-Thalassemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of beta-thalassemia
  • Clinically defined non-transfusion-dependent anemia (Part 1 only), defined as concentrations >7.5 grams per deciliter (g/dL) and \<9.5 g/dL, less than or equal to 4 transfusions of red blood cell units within 1 year prior to study enrollment, and no transfusion within 12 weeks prior to study enrollment
  • Completion of 16 weeks of treatment with bitopertin in Part 1 of this study with more than 80% compliance from expected use of study medication (based on patient diary and study drug accountability; Part 2 only)
  • A favorable benefit-risk ratio from treatment with bitopertin as assessed by the Investigator (Part 2 only)

Exclusion criteria

Exclusion Criteria:

  • Any history of gene therapy
  • History of hemolytic anemia except for beta-thalassemia
  • Severe symptomatic splenomegaly and/or hepatomegaly with hypersplenism (Part 1 only)
  • Any use of an erythropoiesis-stimulating agent within 24 weeks prior to enrollment.
  • Initiation of iron chelation therapy or hydroxyurea within 24 weeks prior to enrollment (Part 1 only)
  • Depression, treatment with anti-depressants, or other psychiatric illnesses and/or drug abuse
  • /uncontrolled comorbid disease
  • Pregnant or breastfeeding females
  • Use of cytochrome P450 (CYP) 3A4 inhibitors within 2 weeks or inducers within 4 weeks prior to study drug
  • Active or C or known positive (HIV) test result
  • Diagnosis of cancer within previous 5 years unless treatment has resulted in complete freedom from disease for at least 2 years
  • Any major illness within 1 month or febrile illness within 1 week prior to study drug
  • Pulmonary hypertension requiring oxygen therapy (Part 1 only)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Bitopertin

    Part 1 - The main study - 16 weeks in total: Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose of bitopertin. Part 2 - Open Label Extension (OLE) - up to an additional 12 months: Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed. Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period.

    Drug: Bitopertin

Interventions

  • Bitopertin will be administered orally once daily at doses up to 120 milligrams (mg).

    Also known as: RO4917838

06

What researchers measure

Primary outcomes

  1. Safety Outcome: Percentage of Participants with Adverse Events (AEs) - Part 1 only

    Time frame: Baseline, Week 16, up to Week 22

  2. Efficacy Outcome: Change in Total Hemoglobin (Hb) Level from Baseline to End of 16-Week Treatment Period in Part 1

    Time frame: Baseline to Week 16

  3. Long-term Safety Outcome : Percentage of Participants with Adverse Events (AEs) - Part 2 only

    Time frame: Baseline to 19 Months

Secondary outcomes

  1. Apparent Clearance of Bitopertin

    Time frame: Part 1: 2,12 hours (H) postdose (PD) on Day 1; 0 H predose (PRD) on Day 2; 0H PRD and 3H PD on Days 15,29,57; 0H PRD and 1,4H PD on Day 85; 0H PRD on Day 113; early withdrawal (ED) up to 22 wks. Part 2: 0H PRD and 1,4H PD on Days 183,365; ED up to 65 wks

  2. Volume of Distribution of Bitopertin

    Time frame: Part 1: 2,12 hours (H) postdose (PD) on Day 1; 0 H predose (PRD) on Day 2; 0H PRD and 3H PD on Days 15,29,57; 0H PRD and 1,4H PD on Day 85; 0H PRD on Day 113; early withdrawal (ED) up to 22 wks. Part 2: 0H PRD and 1,4H PD on Days 183,365; ED up to 65 wks

  3. Area Under the Concentration-Time Curve (AUC) of Bitopertin within a Dosing Interval

    Time frame: Part 1: 2,12 hours (H) postdose (PD) on Day 1; 0 H predose (PRD) on Day 2; 0H PRD and 3H PD on Days 15,29,57; 0H PRD and 1,4H PD on Day 85; 0H PRD on Day 113; early withdrawal (ED) up to 22 wks. Part 2: 0H PRD and 1,4H PD on Days 183,365; ED up to 65 wks

  4. Minimum Observed Concentration (Cmin) of Bitopertin

    Time frame: Part 1: Predose (0 H) on Days 2, 15, 29, 57, 85, 113; and at early withdrawal (up to 22 weeks overall). Part 2: Predose (0 H) and postdose (1, 4 H) on Days 183, 365; and at early withdrawal (up to 65 weeks overall)

  5. Maximum Observed Concentration (Cmax) of Bitopertin

    Time frame: Part 1: 2,12 hours (H) postdose (PD) on Day 1; 0 H predose (PRD) on Day 2; 0H PRD and 3H PD on Days 15,29,57; 0H PRD and 1,4H PD on Day 85; 0H PRD on Day 113; early withdrawal (ED) up to 22 wks. Part 2: 0H PRD and 1,4H PD on Days 183,365; ED up to 65 wks

  6. Apparent Elimination Half-Life of Bitopertin

    Time frame: Part 1: 2,12 hours (H) postdose (PD) on Day 1; 0 H predose (PRD) on Day 2; 0H PRD and 3H PD on Days 15,29,57; 0H PRD and 1,4H PD on Day 85; 0H PRD on Day 113; early withdrawal (ED) up to 22 wks. Part 2: 0H PRD and 1,4H PD on Days 183,365; ED up to 65 wks

  7. Accumulation Ratio of Bitopertin

    Time frame: Part 1: 2,12 hours (H) postdose (PD) on Day 1; 0 H predose (PRD) on Day 2; 0H PRD and 3H PD on Days 15,29,57; 0H PRD and 1,4H PD on Day 85; 0H PRD on Day 113; early withdrawal (ED) up to 22 wks. Part 2: 0H PRD and 1,4H PD on Days 183,365; ED up to 65 wks

  8. Change from Baseline in Absolute Reticulocyte Count

    Time frame: Part 1: Baseline, Week 16. Part 2: Up to Week 65

  9. Change from Baseline in Serum Lactate Dehydrogenase Level

    Time frame: Part 1: Baseline, Week 16. Part 2: Up to Week 65

  10. Change from Baseline in Serum Bilirubin Level

    Time frame: Part 1: Baseline, Week 16. Part 2: Up to Week 65

  11. Change from Baseline in Absolute Red Blood Cell Count

    Time frame: Part 1: Baseline, Week 16. Part 2: Up to Week 65

  12. Change in Total Hb Level from Baseline to the End of the Treatment Period in Part 2

    Time frame: Baseline, 19 Months

07

Study locations

4 sites
  • Centro della Microcitemia e delle Anemie Congenite - Ospedale Galliera; Oncologia /Cardiologia
    Genova, Liguria 16128, Italy
  • Ospedale Maggiore di Milano; Cardio-Metabolic Diseases
    Milano, Lombardia 20122, Italy
  • Chronic Care Center
    Baabda, 1003, Lebanon
  • Siriraj Hospital; Division of Haematology-Oncology
    Bangkok Noi, 10700, Thailand
08

References and documents

Publications

  • Taher AT, Viprakasit V, Cappellini MD, Kraus D, Cech P, Volz D, Winter E, Nave S, Dukart J, Khwaja O, Koerner A, Hermosilla R, Brugnara C. Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent beta-thalassaemia. Br J Haematol. 2021 Jul;194(2):474-477. doi: 10.1111/bjh.17479. Epub 2021 Apr 30. No abstract available. PubMed 33931857 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Jun 2018, 8 months.

Of 29 phase 2 interventional studies under beta-Thalassemia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 57. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2017
First posted
Sep 5, 2017
StartActual
Oct 26, 2017
Primary completionActual
Jun 29, 2018
CompletionActual
Jun 29, 2018
Last update
Oct 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03271541
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 5, 2017
Start date
Oct 26, 2017
Primary completion
Jun 29, 2018
Completion
Jun 29, 2018
Last update
Oct 5, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bitopertin

Start the discussion